Abstract
Irrespective of the ethnic origin of the patient, nasopharyngeal carcinoma (NPC), appears to stimulate the production of IgA antibodies against VCA. These antibodies are detected at high frequency and titres in sera from NPC patients but only rarely from control subjects. A majority of relapse-free survivors tested 1-12 years after radiotherapy (RT) sustain a detectable level of IgA anti-VCA. Serum titres of IgA anti-VCA remain relatively unchaged in individual NPC patients after RT, regardless of the disease evolution. These antibodies were detected in serum from one individual 9 months before NPC and the titre rose concomitantly with its clinical onset. Titres of IgA anti-VCA in multiple serum specimens from individual NPC patients, and in sera from different NPC patients, do not correlate with titres of IgG anti-VCA or with Serum IgA. It thus seems possible that the IgA anti-VCA in the sera of NPC patients might be largely derived near NPC. Apparently healthy individuals showing detectable IgA anti-VCA tend to aggregate in families of NPC patients. The distribution of siblings of these families who have the IgA anti-VCA reaction shows the binomial distribution expected for an autosomal recessive trait, implying the involvement of an autosomal recessive gene in the IgA anti-VCA response.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gerber P., Lucas S., Nonoyama M., Perlin E., Goldstein L. I. Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis. Lancet. 1972 Nov 11;2(7785):988–989. doi: 10.1016/s0140-6736(72)92402-6. [DOI] [PubMed] [Google Scholar]
- Glaser R., de Thé G., Lenoir G., Ho J. H. Superinfection epithelial nasopharyngeal carcinoma cells with Epstein-Barr virus. Proc Natl Acad Sci U S A. 1976 Mar;73(3):960–963. doi: 10.1073/pnas.73.3.960. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Henle G., Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976 Jan 15;17(1):1–7. doi: 10.1002/ijc.2910170102. [DOI] [PubMed] [Google Scholar]
- Henle G., Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol. 1966 Mar;91(3):1248–1256. doi: 10.1128/jb.91.3.1248-1256.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Henle W., Henle G., Zajac B. A., Pearson G., Waubke R., Scriba M. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science. 1970 Jul 10;169(3941):188–190. doi: 10.1126/science.169.3941.188. [DOI] [PubMed] [Google Scholar]
- Ho H. C., Ng M. H., Kwan H. C. IgA antibodies to Epstein-Barr viral capsid antigens in saliva of nasopharyngeal carcinoma patients. Br J Cancer. 1977 Jun;35(6):888–890. doi: 10.1038/bjc.1977.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Klein G., Giovanella B. C., Lindahl T., Fialkow P. J., Singh S., Stehlin J. S. Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A. 1974 Dec;71(12):4737–4741. doi: 10.1073/pnas.71.12.4737. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Trumper P. A., Epstein M. A., Giovanella B. C. Activation in vitro by BUdR of a productive EB virus infection in the epithelial cells of nasopharyngeal carcinoma. Int J Cancer. 1976 May 15;17(5):578–587. doi: 10.1002/ijc.2910170505. [DOI] [PubMed] [Google Scholar]
- Wara W. M., Wara D. W., Phillips T. L., Ammann A. J. Elevated IGA in carcinoma of the nasopharynx. Cancer. 1975 May;35(5):1313–1315. doi: 10.1002/1097-0142(197505)35:5<1313::aid-cncr2820350510>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]